All In Biotech

Drug Trial Radar · NCT07759934

ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

A Multicenter, Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of ASK0912 for Injection Versus Polymyxin B for Injection in Adult Patients With Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 25, 2026

Primary completion

Oct 20, 2027

Study completion Dec 25, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, active-controlled, multicenter phase II clinical trial. The study aims to evaluate the efficacy, safety and tolerability of two different dosing regimens of ASK0912 for Injection compared with Polymyxin B Sulfate for Injection in adult patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by multidrug-resistant or carbapenem-resistant Gram-negative bacilli. Eligible subjects will be randomly assigned to one of three treatment groups: ASK0912 Regimen 1, ASK0912 Regimen 2, or Polymyxin B Sulfate active comparator group. Subjects will receive assigned intravenous study treatment for 7 to 14 days. The primary efficacy endpoints include clinical cure rate at the Test of Cure (TOC) visit and Day 28 all-cause mortality in the modified intent-to-treat (MITT) population. Safety assessments will be conducted throughout the study to monitor adverse events, laboratory parameters and other safety indicators.

Conditions

  • Ventilator-associated Bacterial Pneumonia (VABP)
  • Hospital-acquired Bacterial Pneumonia (HABP)

Interventions

  • ASK0912 for InjectionDrug

    ASK0912 for injection administered at a dose of 0.75 mg/kg every 12 hours

  • ASK0912 for InjectionDrug

    ASK0912 for injection administered at a dose of 0.5 mg/kg every 8 hours

  • Polymyxin B Sulfate for InjectionDrug

    Polymyxin B Sulfate for Injection:Loading dose of 2.0-2.5 mg/kg; maintaining dose 1.25-1.5 mg/kg after 12 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Cure at Test of Cure (TOC) Visit in the Modified Intent to Treat (MITT) PopulationTime frame: Up to approximately 28 days
  2. Percentage of Participants With All-cause Mortality(ACM) Through Day 28 in the Modified Intent to Treat (MITT) PopulationTime frame: Up to approximately 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu AOSAIKANG Pharm

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.